Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1992-08-28
1994-04-19
Wityshyn, Michael G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530380, 530824, 424532, 424 852, 514 21, A61K 3700, A61K 4505
Patent
active
053045424
ABSTRACT:
The invention features a method for inhibiting proliferation of osteoblasts in a mammal in need of such inhibition. The method entails administering PF4. PF4 can be used to treat both diseases characterized by primary changes in osteoblastic cell function/activity (e.g., ossifying fibroma and fibrous dysplasia, osteoblastoma and osteoid osteoma, and osteosarcoma) and diseases or systemic conditions affecting bone in which abnormal osteoblastic cell function/activity is a secondary effect (e.g., acromegaly, hypercalcemia, primary or secondary hyperparathyroidism, hyperthyroidism, osteoporosis, or Paget's disease of bone). In addition, PF4 may be used to treat diseases associated with localized changes in bone metabolism in which abnormal osteoblastic cell function/activity contributes to pathogenic bone changes. For example, PF4 can be used to treat periodontal disease (localized, inflammation-induced bone loss), rheumatoid arthritis and osteoarthritis (localized, inflammation-induced bone loss) localized osteoporosis, mastocytosis, multiple myeloma, and bone metastases of various tumors. Because of its inhibitory effect on osteoblastic cell proliferation, PF4 can be used to treat bone abnormalities associated with either undesired osteoblastic cell proliferation or undesired osteoblastic cell function or activity.
REFERENCES:
patent: 4645828 (1987-02-01), Twardzik et al.
patent: 4702908 (1987-10-01), Thorbecke
patent: 4737580 (1988-04-01), Twardzik et al.
patent: 5086164 (1992-02-01), Maione
patent: 5112946 (1992-05-01), Maione
patent: 5124316 (1992-06-01), Antoniades et al.
patent: 5154921 (1992-10-01), Sager et al.
patent: 5185323 (1993-02-01), Gewirtz
Canalis et al. J. Clin. Invest. 81:277-281 (1988).
Glowacki Life Sciences 33:1019-1024 (1983).
Wood The New England Journal of Medicine 327:620-627 (1992).
Rodan Cancer Research 47:4961-4966 (1987).
Sakamoto Biochim. et Biophysica Acta 385:41-50 (1975).
Horton Biochim. et Biophysics Acta 630:459-461 (1980).
Osterman Biochem. Biophys. Res. Comm. 107:130 (1981).
Hiti-Harper Science 199:991 (1978).
Deuel Proc. Nat'l Acad. Sci USA 78:4585 (1981).
Maione Science 247:77 (1989).
Rucinski Thrombosis & Haematosis 63:493 (1990).
Sayala C.
University of Louisville Research Foundation Inc.
Wityshyn Michael G.
LandOfFree
Use of platelet factor 4 to inhibit osteoblast proliferation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of platelet factor 4 to inhibit osteoblast proliferation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of platelet factor 4 to inhibit osteoblast proliferation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-19791